ライフサイエンスコーパス: corneal neovascularization

1 o induce endothelial cell chemotaxis and rat corneal neovascularization.

2 he VEGF receptor Flt-1 effectively prevented corneal neovascularization.

3 neutralizing antibodies potently suppressed corneal neovascularization.

4 sed to determine the requirement for VEGF in corneal neovascularization.

5 y endothelial cells and cytokine-induced rat corneal neovascularization.

6 10 from IPF-PF CM resulted in an increase in corneal neovascularization.

7 capillary endothelial cell migration and of corneal neovascularization.

8 an objective method for analyzing changes in corneal neovascularization.

9 keratitis lesion severity and the extent of corneal neovascularization.

10 80% of ADAMTS9+/- mice developed spontaneous corneal neovascularization.

11 assessed 7 days after chemical burn-induced corneal neovascularization.

12 normal histology, lack of K12 expression and corneal neovascularization.

13 l keratitis lesions as well as the extent of corneal neovascularization.

14 ncreased TSP-1 and endostatin, and inhibited corneal neovascularization.

15 are effective in suppressing injury-induced corneal neovascularization.

16 bone marrow suppression but did not inhibit corneal neovascularization.

17 st that ephrinB1 plays a synergistic role in corneal neovascularization.

18 BM-derived hematopoietic precursor cells in corneal neovascularization.

19 ulation of VEGF, leukocyte infiltration, and corneal neovascularization.

20 ne essential component in the development of corneal neovascularization.

21 t FasL is an important factor in controlling corneal neovascularization.

22 mon abnormalities were conjunctivitis (51%), corneal neovascularization (44%), dry eye (38%), corneal

23 of VEGF bioactivity potently suppressed both corneal neovascularization (8.3% +/- 8.1% vs. 41.1% +/-

24 Corneal neovascularization, a frequent complication of c

25 val CsA implants do not significantly affect corneal neovascularization after high-risk penetrating k

26 f corneal limbal stem cells often results in corneal neovascularization and an optically inferior epi

27 ssion were measured by immunohistochemistry, corneal neovascularization and capillary tube formation

28 articles to HSV-infected mice led to reduced corneal neovascularization and diminished SK lesions.

29 tial and time-dependent relationship between corneal neovascularization and goblet cell density was a

30 cts of subconjunctival-injected parstatin on corneal neovascularization and inflammation in rats were

31 VEGF-mediated corneal neovascularization and laser-induced choroidal n

32 TLmap to identify HSV-1 SNPs associated with corneal neovascularization and mean peak percentage weig

33 d to investigate the direct effect of PAF on corneal neovascularization and on the expression of angi

34 sed systemically on rats captopril inhibited corneal neovascularization and showed the antitumor acti

35 GF-A, MMP-2, and MMP-9, that are involved in corneal neovascularization and SK pathogenesis.

36 efficacy of PDT-induced vessel regression in corneal neovascularization, and as such the enhanced eff

37 Graft survival, corneal neovascularization, and corneal lymphangiogenesi

38 Graft survival, corneal neovascularization, and corneal lymphangiogenesi

39 solvent evaporation METHOD: Graft survival, corneal neovascularization, and corneal lymphangiogenesi

40 Graft survival, corneal neovascularization, and corneal lymphangiogenesi

41 th, lung compensatory growth, wound healing, corneal neovascularization, and retinal vascularization.

42 inia virus strain WR results in blepharitis, corneal neovascularization, and stromal keratitis.

43 IL-6- and VEGF-mediated corneal neovascularization are blocked by TA through the

44 aganirsen significantly reduced the relative corneal neovascularization area after 90 days by 26.20%

45 Mean corneal neovascularization area at week 52 (visit 12) wa

46 zumab treatment reduced the extent of stable corneal neovascularization as measured by neovascular ar

47 D5AB1 showed an antiangiogenic effect in the corneal neovascularization assay; however, both were eff

48 ed corneal opacity and developed spontaneous corneal neovascularization at older age.

49 The differences in corneal neovascularization between matrilysin-deficient

50 PAF stimulates corneal neovascularization by a receptor-mediated mechan

51 tor levels for at least 5 weeks, and reduced corneal neovascularization by approximately 40% (P = 0.0

52 eal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth fa

53 anophthalmia, retinal dysplasia, keratitis, corneal neovascularization, cataracts, and calcification

54 inflammation (CD45), apoptosis (TUNEL), and corneal neovascularization (CD31) were evaluated 27 and

55 Corneal neovascularization (CNV) was induced by micropel

56 Corneal neovascularization (CNV) was induced by suture o

57 Niaspan also significantly increased corneal neovascularization compared with nontreatment co

58 Ocular infection with HSV causes corneal neovascularization (CV), an essential step in th

59 The ICP4 gene was previously identified as a corneal neovascularization determinant, validating the v

60 ficant difference in incidence and degree of corneal neovascularization developing after penetrating

61 atory response in the eye that may result in corneal neovascularization during blinding immunopatholo

62 Secondary outcome measures were corneal neovascularization following hydrops and complic

63 showed a persistent 34% to 35% inhibition of corneal neovascularization for up to 4 weeks.

64 J/cm(2) resulted in 30% to 50% regression of corneal neovascularization; however, in these animals, a

65 Application of bevacizumab in mice with corneal neovascularization; however, showed variable pen

66 ified as the correlate of protection against corneal neovascularization, HSV-1 shedding, and latency

67 n receptor substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding ph

68 horoidal neovascularization and VEGF-induced corneal neovascularization in AIF-deficient mice.

69 lar endothelial growth factor (VEGF)-induced corneal neovascularization in C57BL/6 mice was used to e

70 assays were performed to compare the area of corneal neovascularization in matrilysin-deficient mice

71 The area of corneal neovascularization in matrilysin-deficient mice

72 The mean percentage area of corneal neovascularization in mice 3 weeks after corneal

73 last growth factor (bFGF) was used to induce corneal neovascularization in mice.

74 aganirsen eye drops significantly inhibited corneal neovascularization in patients with keratitis.

75 ay be useful for the objective evaluation of corneal neovascularization in the future.

76 Corneal neovascularization in the matrilysin-deficient m

77 asic fibroblast growth factor (bFGF)-induced corneal neovascularization in vivo and in vitro.

78 d differentiated EPCs in vitro and augmented corneal neovascularization in vivo.

79 lial cells in vivo, and induce regression of corneal neovascularization in vivo.

80 Corneal neovascularization increases the risk of T cell-

81 thelial growth factor in vitro and inhibited corneal neovascularization induced by basic fibroblast g

82 ng pathway in a murine model of inflammatory corneal neovascularization induced by mechanical injury

83 s can inhibit and cause regression of murine corneal neovascularization induced by mechanical-chemica

84 been sutured into BALB/c recipient beds with corneal neovascularization induced by placement of three

85 Corneal neovascularization is a vision-threatening condi

86 Corneal neovascularization is critical for the progressi

87 This noninflammatory model of corneal neovascularization is especially advantageous be

88 Corneal neovascularization is one of the leading causes

89 The role of VEGF in inflammatory corneal neovascularization is unknown and was investigat

90 Corneal neovascularization leads to loss of immune privi

91 uggest that MT1-MMP potentiates bFGF-induced corneal neovascularization, likely by modulating the bFG

92 of endostatin-producing cells, resulting in corneal neovascularization, massive infiltration of effe

93 a basic fibroblast growth factor-induced rat corneal neovascularization model.

94 h and regression were determined in a murine corneal neovascularization model.

95 LB/c) with intact corneas (n = 14), and with corneal neovascularization (n = 14).

96 ndary end points included area of pathologic corneal neovascularization, need for transplantation, ri

97 Corneal neovascularization (NV) is a sight-threatening c

98 For assessment of corneal neovascularization (NV), a quantitative method w

99 The incidence and degree of corneal neovascularization occurring after penetrating k

100 r: age, sex, risk factors for graft failure (corneal neovascularization, ocular surface disease, glau

101 n, glaucoma, postoperative steroid response, corneal neovascularization or peripheral anterior synech

102 ial rejection as age </=25 years (P = .017), corneal neovascularization (P = .001), donor trephinatio

103 A comparison of corneal neovascularization parameters was undertaken bef

104 ects on existing ocular neovascular lesions (corneal neovascularization), PDT monotherapy yielded an

105 Corneal neovascularization preceded the appearance of go

106 d 19, in addition to confirming our previous corneal neovascularization QTLs of AngVq1 and AngFq2.

107 Corneal neovascularization represents a key step in the

108 ceived xenografts or cautery manifested less corneal neovascularization than did control animals afte

109 ad a significantly greater effect on induced corneal neovascularization than did TSP-2(-/-), with the

110 ators of the inflammatory and VEGF-dependent corneal neovascularization that follows limbal injury.

111 The increase in corneal neovascularization was associated with heightene

112 biomicroscopy and fluorescein staining, and corneal neovascularization was confirmed by india ink pe

113 ea, the role of this molecule in controlling corneal neovascularization was examined in this study.

114 Corneal neovascularization was induced in Dutch belted r

115 Besides, corneal neovascularization was much more extended in SLP

116 Corneal neovascularization was present at the time of PK

117 mouse model of suture-induced, inflammatory corneal neovascularization was used to evaluate the lack

118 To determine whether the differences in corneal neovascularization were related to differences i

119 dence that EPCs that contributed to enhanced corneal neovascularization were specifically mobilized f

120 nerves were detected in the areas subject to corneal neovascularization, whereas they persisted in th

121 ls stimulated endothelial cell migration and corneal neovascularization, whereas those from NU cells

122 Using antiangiogenesis treatment to prevent corneal neovascularization, which revokes immune privile

123 PIGF129/VEGF165 heterodimers also induce corneal neovascularization with a maximal vessel length

124 Subconjunctival parstatin inhibited corneal neovascularization, with 200 mug the most effect

125 al neovascularization, growth factor-induced corneal neovascularization, wound healing, and Matrigel